Business Context and Reporting Period
This Form 8-K Current Report was filed by iBio, Inc. on August 13, 2020, covering events occurring on August 7, 2020. The filing primarily addresses the unregistered sale of equity securities resulting from the conversion of preferred stock.
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure changes.
Material Changes
- Preferred Stock Conversion: On August 7, 2020, Eastern Capital Limited converted 5,785 shares of the Company's Series B Preferred Stock into 28,925,000 shares of common stock.
- Conversion Price: The conversion was executed at a stated price of $0.20 per share.
- Capital Structure Update: As of August 12, 2020, the total number of common stock shares outstanding increased to 174,415,206.
- Regulatory Basis: The issuance was made in reliance on the exemption from registration provided under Section 3(a)(9) of the Securities Act of 1933.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies beyond the specific transaction details. No unusual items were reported.
Investor Verification Checklist
- Verify the updated total share count of 174,415,206 in subsequent filings.
- Confirm the dilution impact of the 28,925,000 newly issued shares on existing shareholders.
- Review the terms of the Series B Preferred Stock to understand the conversion mechanics and any remaining preferred equity.
- Check for any related press releases or agreements with Eastern Capital Limited regarding the conversion.